Two weeks of hydrogen inhalation can significantly reverse adaptive and innate immune system senescence patients with advanced non-small cell lung cancer: a self-controlled study.
Ji-Bing Chen, Xiao-Feng Kong, Wei Qian, Feng Mu, Tian-Yu Lu, You-Yong Lu, Ke-Cheng Xu · Medical gas research · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 20 patients with advanced non-small cell lung cancer, after 2 weeks of hydrogen therapy, the number of exhausted and senescent cytotoxic T cells decreased to within the normal range, and there was an increase in killer Vδ1 cells. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 20 patients with advanced non-small cell lung cancer. After 2 weeks of hydrogen therapy, the number of exhausted and senescent cytotoxic T cells decreased to within the normal range, and there was an increase in killer Vδ1 cells.
What the Researchers Studied
The researchers studied 20 patients with advanced non-small cell lung cancer. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 66.7% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 66.7% source-reported H₂ gas concentration; 3 L/min total gas flow (approximately 2001 mL/min H₂ component); reported treatment duration: 2 weeks. After 2 weeks of hydrogen therapy, the number of exhausted and senescent cytotoxic T cells decreased to within the normal range, and there was an increase in killer Vδ1 cells. The authors concluded that the current data indicate that the immunosenescence of advanced non-small cell lung cancer involves nearly all lymphocyte subsets, and 2 weeks of hydrogen treatment can significantly improve most of these indexes. Surprisingly, after hydrogen therapy, the proportion of regulatory T cells in the blood decreased significantly, demonstrating that hydrogen can control tumor progress with different mechanisms.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 20 patients with advanced non-small cell lung cancer. The study used a human clinical study. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 66.7% source-reported H₂ gas concentration. The reported treatment duration was 2 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.